Sunshine Biopharma majority holder approves >20% share issuance at discount to market

Filed May 29, 2026 · Period ending May 28, 2026 · ~1 min read

Key Changes

• high

  Majority shareholder (86% voting control) approved issuing over 20% of outstanding shares at below-market price for May 19 offering, triggering significant dilution to existing holders at a discount.

  Item 5.07 verify on EDGAR →
• high

  Company granted authority to voluntarily lower exercise price on Series C Warrants at any time, potentially increasing dilution beyond original terms if management reprices warrants to encourage exercise.

  Item 5.07 verify on EDGAR →
• medium

  Series C Warrants from May offering include automatic adjustment provisions protecting warrant holders from dilution in share combination events, which could increase shares issued upon exercise.

  Item 5.07 verify on EDGAR →